Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | BTK | Q06187 | 1/20 | 0.42 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.34 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19853319 | 1.00 | HSD17B10 (0.49) | HSD17B10SMN1; SMN2BTKNR1H2CHRM2 | |
| SCHEMBL1198433 | 0.90 | HSD17B10 (0.47) | HSD17B10SMN1; SMN2BTKNR1H2CHRM2 | |
| SCHEMBL13481736 | 0.90 | HSD17B10 (0.47) | HSD17B10SMN1; SMN2BTKNR1H2CHRM2 | |
| SCHEMBL29015468 | 0.90 | HSD17B10 (0.44) | HSD17B10SMN1; SMN2BTKNR1H2CHRM2 | |
| SCHEMBL29015465 | 0.90 | HSD17B10 (0.44) | HSD17B10SMN1; SMN2BTKNR1H2CHRM2 | |
| SCHEMBL30402912 | 0.90 | HSD17B10 (0.44) | HSD17B10SMN1; SMN2BTKNR1H2CHRM2 | |
| SCHEMBL3194210 | 0.90 | HSD17B10 (0.47) | HSD17B10SMN1; SMN2BTKNR1H2CHRM2 | |
| SCHEMBL10591305 | 0.89 | HSD17B10 (0.43) | HSD17B10SMN1; SMN2BTKNR1H2CHRM2 | |
| SCHEMBL7730850 | 0.88 | HSD17B10 (0.42) | HSD17B10SMN1; SMN2BTKNR1H2CHRM2 | |
| SCHEMBL21527750 | 0.88 | HSD17B10 (0.45) | HSD17B10SMN1; SMN2BTKNR1H2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3490994-B1 | SPIRO-LACTAM AND BIS-SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | APTINYX INC (US) | 2024-02-07 | — | — | EP | disclosed |
| CN-109661398-B | Spiro-lactam and di-spiro-lactam NMDA receptor modulators and uses thereof | 阿普廷伊克斯股份有限公司 | 2022-07-05 | — | — | CN | disclosed |
| US-20220098211-A1 | SPIRO-LACTAM AND BIS-SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | APTINYX INC. | 2022-03-31 | — | — | US | disclosed |
| US-11028095-B2 | Spiro-lactam and bis-spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-11028095-B2 | Spiro-lactam and bis-spiro-lactam NMDA receptor modulators and uses thereof | APTINYX INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-20200181159-A1 | SPIRO-LACTAM AND BIS-SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2020-06-11 | — | — | US | disclosed |
| US-20200181159-A1 | SPIRO-LACTAM AND BIS-SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2020-06-11 | — | — | US | disclosed |
| WO-2018026792-A1 | SPIRO-LACTAM AND BIS-SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | APTINYX INC. (US) | 2018-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200181159-A1 | SPIRO-LACTAM AND BIS-SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN2C | HSD17B10 2463/4885SMN1; SMN2 1457/4885BTK 2362/4885 |
| US-20220098211-A1 | SPIRO-LACTAM AND BIS-SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN2C | HSD17B10 2463/4885SMN1; SMN2 1457/4885BTK 2362/4885 |
| US-11028095-B2 | Spiro-lactam and bis-spiro-lactam NMDA receptor modulators and uses thereof | GRIN1, GRIN2A, GRIN2C | HSD17B10 2463/4885SMN1; SMN2 1457/4885BTK 2362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.